Feature | July 25, 2012

FDA Clears First Robotic System for Coronary Stent Procedures

Corindus wins 510(k) clearance for CorPath 200 robotic-assisted PCI system to enhance control and protect physicians from radiation

The CorPath 200 cath lab robotic system is designed for more precise movements and less radiation exposure to physicians during PCI.

The CorPath system was shown in a hybrid OR display at the American College of Cardiology (ACC) 2012 meeting.

July 25, 2012 — Corindus Vascular Robotics today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the CorPath 200 robotic-assist system for use in percutaneous coronary interventions (PCI).

“The FDA clearance of the CorPath system will truly change the way I am able to practice,” said Joseph P. Carrozza Jr., M.D., chief of cardiovascular medicine at St. Elizabeth’s Medical Center in Boston. “As interventional cardiologists, we perform our procedures using X-ray guidance and are cognizant that throughout our careers we will be exposed to a high amount of radiation. In the past, we have relied on heavy lead aprons to protect us from radiation, but the physical stress of wearing these aprons can lead to back pain, fatigue and orthopedic injuries.”

Recent data published in Catheterization and Cardiovascular Intervention journal indicated that an interventional cardiologist’s daily exposure to radiation and the physical stresses inherent in the cath lab can lead to occupational health risks — including orthopedic problems, cataracts and cancer. CorPath PRECISE Trial was a prospective, single-arm, multi-center study, which served as the basis for the submission of an FDA clearance application. It demonstrated that robotically assisted PCI is safe and feasible for patients. PCI was successfully completed without having to convert to manual PCI in 98.8 percent of patients and without device-related complications. The overall procedure success rate was 97.6 percent. Additionally, the trial found that robotic-assisted PCI can make the procedure safer for the interventional cardiologist by reducing the radiation exposure by 95 percent when performing the procedure with the CorPath 200 system. 

“I was impressed with its performance and the precise control of the interventional devices, including manipulating the guidewire and stent, being able to move the devices precisely in increments as small as one millimeter,” said Giora Weisz, M.D., director of clinical research at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center, New York. “Working with this robotic technology is very intuitive and the PRECISE trial demonstrated its applicability in today’s cath lab environment. I strongly believe robotic-assisted PCI will enhance the way we are conducting PCI, and we are looking forward to adopting it in our everyday practice.”

The CorPath 200 is the first and only robotic-assisted procedure to allow for controlled placement of coronary guidewires and stent/balloon catheters from an optimized interventional cockpit. The lead-lined cockpit protects the interventional cardiologist from harmful radiation exposure, and the seated position in front of monitors may provide enhanced view of the angiography screen while reducing fatigue and minimizing head, neck and back strain.

In June, Hansen Medical Inc. received FDA 510(k) market clearance for its Magellan Robotic System, the first robotic navigation system to more precisely guide peripheral artery disease (PAD) interventions in the cath lab.

For more information: www.corindus.com

 

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Overlay Init